Journal: Frontiers in virology (Lausanne, Switzerland)
Article Title: RSV infection of humanized lung-only mice induces pathological changes resembling severe bronchiolitis and bronchopneumonia
doi: 10.3389/fviro.2024.1380030
Figure Lengend Snippet: (A) LoM were administered a single intramuscular dose of palivizumab 24 h prior to RSV A2-GFP exposure (15mg/kg or 30mg/kg) or 24 h post-RSV A2-GFP exposure (30mg/kg). Untreated RSV-GFP infected LoM served as a control. (B) GFP+ cells in human lung implants 4 days post-RSV exposure in untreated LoM (n=7 implants) and LoM administered palivizumab pre (15 mg/kg, n=6 implants and 30 mg/kg, n=3 implants) or post (n=4 implants) RSV exposure. (C) Ribavirin was administered to mice once daily (40 mg/kg, intraperitoneal) starting 24 h before or after RSV exposure. Untreated RSV-Luc infected LoM served as a control. (D) Bioluminescence signal (radiance [p sec–1 cm–2 sr–1] represented as total flux) in human lung implants just prior to RSV-exposure and 7 days post-RSV exposure in untreated LoM (white bars, n= 5 implants) and LoM administered ribavirin treatment initiated pre (orange bars, n=6 implants) or post (green bars, n= 6 implants) RSV exposure. The mean (horizontal line) and standard deviation (vertical line) are shown. Background luminescence measured pre-exposure is denoted by the dashed line. (E) Immunohistochemical staining for RSV antigen (brown) in human lung implants 7 days post RSV exposure in untreated LoM (left panel) and LoM administered ribavirin treatment-initiated pre (middle panel) or post (right panel) RSV exposure (scale bars, 100 um; n=3 implants analyzed). (B and D) Data are shown as mean ± SD. Results from treated groups were compared to untreated controls using a two-tailed Kruskal-Wallis test and P values were adjusted for multiple testing using the Benjamini, Krieger, Yekutieli false-discovery rate method.
Article Snippet: Viruses and in vivo analysis of infection Stocks of RSV strain A2 expressing green fluorescent protein (GFP) ( 21 ) or firefly luciferase (Luc) reporter genes were obtained from Viratree.
Techniques: Infection, Control, Standard Deviation, Immunohistochemical staining, Staining, Two Tailed Test
ATCC is a verified supplier 
ATCC manufactures this product 
![(A) LoM were administered a single intramuscular dose of palivizumab 24 h prior to <t>RSV</t> <t>A2-GFP</t> exposure (15mg/kg or 30mg/kg) or 24 h post-RSV A2-GFP exposure (30mg/kg). Untreated RSV-GFP infected LoM served as a control. (B) GFP+ cells in human lung implants 4 days post-RSV exposure in untreated LoM (n=7 implants) and LoM administered palivizumab pre (15 mg/kg, n=6 implants and 30 mg/kg, n=3 implants) or post (n=4 implants) RSV exposure. (C) Ribavirin was administered to mice once daily (40 mg/kg, intraperitoneal) starting 24 h before or after RSV exposure. Untreated RSV-Luc infected LoM served as a control. (D) Bioluminescence signal (radiance [p sec–1 cm–2 sr–1] represented as total flux) in human lung implants just prior to RSV-exposure and 7 days post-RSV exposure in untreated LoM (white bars, n= 5 implants) and LoM administered ribavirin treatment initiated pre (orange bars, n=6 implants) or post (green bars, n= 6 implants) RSV exposure. The mean (horizontal line) and standard deviation (vertical line) are shown. Background luminescence measured pre-exposure is denoted by the dashed line. (E) Immunohistochemical staining for RSV antigen (brown) in human lung implants 7 days post RSV exposure in untreated LoM (left panel) and LoM administered ribavirin treatment-initiated pre (middle panel) or post (right panel) RSV exposure (scale bars, 100 um; n=3 implants analyzed). (B and D) Data are shown as mean ± SD. Results from treated groups were compared to untreated controls using a two-tailed Kruskal-Wallis test and P values were adjusted for multiple testing using the Benjamini, Krieger, Yekutieli false-discovery rate method.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_9974/pmc11339974/pmc11339974__nihms-1996204-f0004.jpg)